SOLIGENIX INC

On May 5, 2025, we entered into an amendment (the “Amendment”) to our employment agreement with Christopher J. Schaber, PhD, our President and Chief Executive Officer. Pursuant to the Amendment, we increased, from 2,084 shares to 200,000 shares, the number of shares of common stock that we would issue to Dr. Schaber prior to the completion of a transaction, or series or combination of related transactions, negotiated by our Board of Directors whereby a majority of our capital stock or a majority of our assets are transferred from us and/or our stockholders to a third party. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

During the quarter ended March 31, 2025, no directors orofficers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.